• user warning: Table './fnndrupaldev/term_node' is marked as crashed and last (automatic?) repair failed query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 478086 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT COUNT(sid) AS count FROM sessions WHERE timestamp >= 1419149850 AND uid = 0 in /var/www/www.fnno.com/htdocs/includes/session.inc on line 111.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT DISTINCT u.uid, u.name, s.timestamp FROM users u INNER JOIN sessions s ON u.uid = s.uid WHERE s.timestamp >= 1419149850 AND s.uid > 0 ORDER BY s.timestamp DESC in /var/www/www.fnno.com/htdocs/modules/user/user.module on line 765.

Possible Bearish Inside Day Candle Pattern Detected for Spectrum Pharmaceuticals (NASDAQ:SPPI)

Published on Mon, 04/15/2013 - 07:29
By Peter Chu

Analysts have spotted a possible bearish inside day candle pattern in Spectrum Pharmaceuticals (NASDAQ:SPPI) based on the price action in the company's shares. Yesterday's price range of $7.17 and $7.29 is within the prior day's high and low of the day. This trading action often signifies indecision by bulls and bears to drive prices higher or lower and often implies a possible change in trend. Owners of Spectrum Pharmaceuticals may want to consider a possible hedge in the event a pullback occurs. Look for confirmation in the next few trading days.

Over the past year, Spectrum Pharmaceuticals has traded in a range of $6.92 to $17.48 and closed yesterday at $7.26, 5% above that low. The 200-day and 50-day moving averages have moved 1.33% lower and 4.49% lower over the past week, respectively.

Spectrum Pharmaceuticals Inc. develops in-licensed drugs for the treatment and supportive care of cancer patients. The Company's satraplatin is an oral, anti-cancer drug. Spectrum's Elsamitrucin targets non-Hodgkin's lymphoma, and Neoquin is being studied in the treatment of superficial bladder cancer. Spectrum also has a pipeline of pre-clinical neurological drug candidates.

Spectrum Pharmaceuticals (NASDAQ:SPPI) has potential upside of 179.9% based on a current price of $7.26 and analysts' consensus price target of $20.33. The stock should find initial resistance at its 50-day moving average (MA) of $9.86 and further resistance at its 200-day MA of $11.85.

By Peter Chu
pchu@fnno.com

Latest News from FNNO

Earnings Look Back: Genesco Is Up 5.1% S...

When Genesco (NYSE:GCO) reported earnings two weeks ago on December 5th, 2014, analysts ...

Post Earnings Update: Vail Resorts Has C...

12 days ago, on December 8th, 2014, Vail Resorts (NYSE:MTN) reported its earnings. Ana ...

Cantel Medical Earnings Review: 10 Days ...

10 days ago, on December 10th, 2014, Cantel Medical (NYSE:CMN) reported its earnings. ...

ABM Industries Earnings Review: 12 Days ...

12 days ago, on December 8th, 2014, ABM Industries (NYSE:ABM) reported its earnings. A ...

Post Earnings Update: Gildan Activewear ...

Two weeks ago on December 4th, 2014 Gildan Activewear (NYSE:GIL) reported earnings and ...

Earnings Look Back: Christopher & Banks ...

When Christopher & Banks (NYSE:CBK) reported earnings two weeks ago on December 4th, 20 ...

Post Earnings Update: Methode Electronic...

9 days ago, on December 11th, 2014, Methode Electronics (NYSE:MEI) reported its earning ...

Phillips-Van Heusen Earnings In Retrospe...

Two weeks ago on December 3rd, 2014 Phillips-Van Heusen (NYSE:PVH) reported earnings an ...